Company news
Shenzhen Chipscreen Biosciences Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release Tablets
January 5, 2026
Announcement on Voluntary Disclosure on the Acceptance of the Clinical Trial Application for CS08399 Tablets
December 31, 2025
Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards
December 29, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
December 23, 2025
Announcement on Voluntary Disclosure of the Inclusion of the Company’s Product in the National Medical Insurance Catalog
December 7, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
December 5, 2025
Announcement on Obtaining Reply of Registration Approval of Application for Issuance of Shares to Specific Objects from China Securities Regulatory Commission
December 2, 2025
Announcement on Equity Change of Shareholder with Over 5% Shares Reaching 1% Scale and Result of Shareholding Reduction
November 26, 2025
Announcement on Resolutions of the 18th Meeting of the 3rd Board of Directors
November 19, 2025
Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for Chiauranib Capsules for Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
November 6, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Restrictions Concerning Share Repurchase
November 5, 2025
Announcement on Non-compliance with Exercise Conditions in the 4th Exercise Period of 2021 Stock Appreciation Right Incentive Plan and Cancellation of This Part of Stock Appreciation Rights
October 31, 2025
Report for Q3 2025
October 30, 2025
Announcement on Receiving Notice of Review Opinions from Shanghai Stock Exchange for Application for the Issuance of A-shares to Specific Objects in 2024
October 29, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 24, 2025
Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 5% Scale
October 16, 2025
Indicative Announcement on Reply to Letter of Review and Inquiry on Application Documents for A-shares Issuance to Specific Objects in 2024
September 24, 2025
Special Report on the Use of Previously Raised Funds
September 15, 2025
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
September 10, 2025
Announcement on Resignation of Senior Management Member
September 1, 2025
2025 Semi-annual Report
August 25, 2025
Announcement on Acceptance of Application for Issuance of A Shares to Specific Objects in 2024 by SSE
August 22, 2025
Announcement on Continuing to Use Temporarily Idle Raised Funds for Cash Management
August 18, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 14, 2025
Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
July 31, 2025
Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025
July 17, 2025
Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma
July 9, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 3, 2025